Form 8-K - Current report:
SEC Accession No. 0001193125-24-250665
Filing Date
2024-11-04
Accepted
2024-11-04 16:40:30
Documents
18
Period of Report
2024-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d907269d8k.htm   iXBRL 8-K 36659
2 EX-1.1 d907269dex11.htm EX-1.1 243455
3 EX-1.2 d907269dex12.htm EX-1.2 165758
4 EX-5.1 d907269dex51.htm EX-5.1 11509
5 EX-99.1 d907269dex991.htm EX-99.1 11452
9 GRAPHIC g907269new_3capture.jpg GRAPHIC 11873
  Complete submission text file 0001193125-24-250665.txt   729067

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA kalv-20241104.xsd EX-101.SCH 2853
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20241104_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20241104_pre.xml EX-101.PRE 11263
20 EXTRACTED XBRL INSTANCE DOCUMENT d907269d8k_htm.xml XML 3648
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 241424247
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)